Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Machine Learning-Based Text Processing Reveals Research Trends in Heterotopic Ossification.

Analytical cellular pathology (Amsterdam)·2026
Same author

Neuroimaging evidence of mitochondrial dysfunction and inflammation in psychiatric disorders: a review.

Psychoradiology·2026
Same author

Single-cell-marker-based subtyping and multi-level analyses uncover the prognostic effects, dysregulations and therapeutic indicative potential of an eight-gene signature in lung adenocarcinoma.

Cancer cell international·2026
Same author

Sublexical semantic decoding during incidental novel word learning in natural Chinese reading.

Cognitive psychology·2026
Same author

CsFDL1-CsFTL3 Complex Represses CsFTL3 via Negative Feedback to Fine-Tune Flowering in Chrysanthemum seticuspe.

Plant, cell & environment·2026
Same author

Effects of Word Frequency, Word Length, and Visual Complexity on Chinese Sentence Oral Reading: An Eye Movement Comparison Study Between Children and Adults.

Journal of eye movement research·2026

相关实验视频

Updated: Sep 10, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

糖屏蔽使得TCR充足的全基性CAR-T疗法成为可能

Zeguang Wu1, Jinhong Shi2, Qiezhong Lamao1

  • 1Biomedical Pioneering Innovation Center, Peking-Tsinghua Center for Life Sciences, Peking University Genome Editing Research Center, State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking University, Beijing 100871, China; Changping Laboratory, Beijing 102206, China.

Cell
|August 22, 2025
PubMed
概括

在T细胞中信号类3 (SPPL3) 缺失促进了对全基性CAR- T治疗的免疫逃避. 这种策略增强了CAR-T细胞的持久性,并减少了排斥,显示出对通用治疗的希望.

关键词:
一个CAR-T单元激活诱导的细胞死亡异种免疫全基因组的CRISPR选甘氨酸移植对宿主疾病主体与移植自然杀手细胞复发性/耐火性B-NHL信号类酶3

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

相关实验视频

Last Updated: Sep 10, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.0K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

科学领域:

  • 免疫学
  • 细胞治疗
  • 葡萄糖生物学

背景情况:

  • 基化学抗原受体 (CAR) - T细胞疗法面临着T细胞持久性和免疫排斥的挑战.
  • 调节T细胞表面特性对于在普遍的CAR-T应用中克服这些限制至关重要.

研究的目的:

  • 调查信号类3 (SPPL3) 在T细胞免疫逃避中的作用.
  • 在临床前和临床环境中评估SPPL3删除的异性CAR- T细胞的安全性和有效性.

主要方法:

  • 在初级T细胞中删除SPPL3,以改变甘氨酸的形状并评估免疫逃避.
  • 开发和测试SPPL3无,T细胞受体 (TCR) 缺乏和TCR充足的抗CD19CAR-T细胞.
  • 在患有复发/ 耐药B细胞非霍奇金淋巴瘤 (B-NHL) 的患者中进行I期临床试验 (NCT06014073).

主要成果:

  • 在不影响CAR功能的情况下,SPPL3的删除导致了糖介导的免疫逃避,降低了全基性T细胞免疫力.
  • 在SPPL3-null,TCR缺少的CAR-T细胞的I期试验中,安全性终点得到满足,细胞因子释放综合征 (CRS) 得到控制.
  • 在SPPL3-null,TCR-充足的CAR-T细胞中,在同情护理病例中没有移植对宿主疾病的迹象.

结论:

  • 删除SPPL3是一种可行的糖屏蔽策略,增强异性CAR-T细胞的免疫逃避.
  • 这种方法有望开发更安全,更有效的通用CAR-T疗法.
  • 突出了TCR在T细胞持久性中的作用,指导了CAR-T细胞设计的进一步优化.